NOVAVAX INC (NVAX) Fundamental Analysis & Valuation

NASDAQ:NVAX • US6700024010

Current stock price

9.34 USD
+0.08 (+0.86%)
At close:
9.35 USD
+0.01 (+0.11%)
After Hours:

This NVAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. NVAX Profitability Analysis

1.1 Basic Checks

  • In the past year NVAX was profitable.
  • NVAX had a negative operating cash flow in the past year.
  • In the past 5 years NVAX reported 4 times negative net income.
  • In the past 5 years NVAX reported 4 times negative operating cash flow.
NVAX Yearly Net Income VS EBIT VS OCF VS FCFNVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B -1.5B

1.2 Ratios

  • NVAX has a Return On Assets of 37.42%. This is amongst the best in the industry. NVAX outperforms 98.07% of its industry peers.
  • NVAX has a better Return On Invested Capital (62.10%) than 99.61% of its industry peers.
Industry RankSector Rank
ROA 37.42%
ROE N/A
ROIC 62.1%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVAX Yearly ROA, ROE, ROICNVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K 3K 4K 5K

1.3 Margins

  • Looking at the Profit Margin, with a value of 39.19%, NVAX belongs to the top of the industry, outperforming 96.92% of the companies in the same industry.
  • NVAX has a better Operating Margin (50.13%) than 99.81% of its industry peers.
  • NVAX has a Gross Margin of 93.50%. This is amongst the best in the industry. NVAX outperforms 94.22% of its industry peers.
  • NVAX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 50.13%
PM (TTM) 39.19%
GM 93.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.75%
GM growth 5YN/A
NVAX Yearly Profit, Operating, Gross MarginsNVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NVAX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NVAX is creating value.
  • There is no outstanding debt for NVAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NVAX Yearly Shares OutstandingNVAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
NVAX Yearly Total Debt VS Total AssetsNVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • Based on the Altman-Z score of -1.68, we must say that NVAX is in the distress zone and has some risk of bankruptcy.
  • NVAX has a Altman-Z score (-1.68) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.68
ROIC/WACC6.41
WACC9.68%
NVAX Yearly LT Debt VS Equity VS FCFNVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

  • NVAX has a Current Ratio of 2.13. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
  • NVAX has a worse Current ratio (2.13) than 74.76% of its industry peers.
  • NVAX has a Quick Ratio of 2.10. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of NVAX (2.10) is worse than 72.64% of its industry peers.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 2.1
NVAX Yearly Current Assets VS Current LiabilitesNVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. NVAX Growth Analysis

3.1 Past

  • NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 246.06%, which is quite impressive.
  • The Revenue has grown by 64.69% in the past year. This is a very strong growth!
  • The Revenue has been growing by 18.76% on average over the past years. This is quite good.
EPS 1Y (TTM)246.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%113.25%
Revenue 1Y (TTM)64.69%
Revenue growth 3Y-17.24%
Revenue growth 5Y18.76%
Sales Q2Q%66.61%

3.2 Future

  • NVAX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -26.41% yearly.
  • NVAX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -16.02% yearly.
EPS Next Y-115.02%
EPS Next 2Y-45.1%
EPS Next 3Y-45.59%
EPS Next 5Y-26.41%
Revenue Next Year-62.38%
Revenue Next 2Y-49.4%
Revenue Next 3Y-30.54%
Revenue Next 5Y-16.02%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NVAX Yearly Revenue VS EstimatesNVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
NVAX Yearly EPS VS EstimatesNVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

3

4. NVAX Valuation Analysis

4.1 Price/Earnings Ratio

  • NVAX is valuated cheaply with a Price/Earnings ratio of 3.88.
  • 99.23% of the companies in the same industry are more expensive than NVAX, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 25.50, NVAX is valued rather cheaply.
  • NVAX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 3.88
Fwd PE N/A
NVAX Price Earnings VS Forward Price EarningsNVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NVAX is valued cheaper than 99.42% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.89
NVAX Per share dataNVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as NVAX's earnings are expected to decrease with -45.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.1%
EPS Next 3Y-45.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NVAX Dividend Analysis

5.1 Amount

  • NVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NVAX Fundamentals: All Metrics, Ratios and Statistics

NOVAVAX INC

NASDAQ:NVAX (3/25/2026, 5:51:22 PM)

After market: 9.35 +0.01 (+0.11%)

9.34

+0.08 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12
Earnings (Next)05-06
Inst Owners69.59%
Inst Owner Change8.05%
Ins Owners0.45%
Ins Owner Change24.13%
Market Cap1.52B
Revenue(TTM)1.12B
Net Income(TTM)440.30M
Analysts73.33
Price Target13.15 (40.79%)
Short Float %32.84%
Short Ratio9.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)59.42%
Min EPS beat(2)-3.3%
Max EPS beat(2)122.14%
EPS beat(4)3
Avg EPS beat(4)313.42%
Min EPS beat(4)-3.3%
Max EPS beat(4)827.96%
EPS beat(8)5
Avg EPS beat(8)145.48%
EPS beat(12)8
Avg EPS beat(12)93.83%
EPS beat(16)8
Avg EPS beat(16)32.84%
Revenue beat(2)2
Avg Revenue beat(2)61.87%
Min Revenue beat(2)59.82%
Max Revenue beat(2)63.92%
Revenue beat(4)4
Avg Revenue beat(4)68.08%
Min Revenue beat(4)58.52%
Max Revenue beat(4)90.08%
Revenue beat(8)6
Avg Revenue beat(8)33.38%
Revenue beat(12)8
Avg Revenue beat(12)28%
Revenue beat(16)9
Avg Revenue beat(16)15.62%
PT rev (1m)0%
PT rev (3m)1.75%
EPS NQ rev (1m)-23.08%
EPS NQ rev (3m)-23.08%
EPS NY rev (1m)-14.54%
EPS NY rev (3m)22.26%
Revenue NQ rev (1m)-22.6%
Revenue NQ rev (3m)-22.6%
Revenue NY rev (1m)4.88%
Revenue NY rev (3m)12.34%
Valuation
Industry RankSector Rank
PE 3.88
Fwd PE N/A
P/S 1.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.89
EPS(TTM)2.41
EY25.8%
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-1.54
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS6.9
BVpS-0.78
TBVpS-1.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 37.42%
ROE N/A
ROCE 78.6%
ROIC 62.1%
ROICexc N/A
ROICexgc N/A
OM 50.13%
PM (TTM) 39.19%
GM 93.5%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.75%
GM growth 5YN/A
F-Score6
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.42
Cap/Depr 20.14%
Cap/Sales 0.49%
Interest Coverage 37.43
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.13
Quick Ratio 2.1
Altman-Z -1.68
F-Score6
WACC9.68%
ROIC/WACC6.41
Cap/Depr(3y)59.16%
Cap/Depr(5y)189.97%
Cap/Sales(3y)2.63%
Cap/Sales(5y)3.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)246.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%113.25%
EPS Next Y-115.02%
EPS Next 2Y-45.1%
EPS Next 3Y-45.59%
EPS Next 5Y-26.41%
Revenue 1Y (TTM)64.69%
Revenue growth 3Y-17.24%
Revenue growth 5Y18.76%
Sales Q2Q%66.61%
Revenue Next Year-62.38%
Revenue Next 2Y-49.4%
Revenue Next 3Y-30.54%
Revenue Next 5Y-16.02%
EBIT growth 1Y342.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-104.45%
EBIT Next 3Y-28.29%
EBIT Next 5YN/A
FCF growth 1Y-149.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-180.34%
OCF growth 3YN/A
OCF growth 5YN/A

NOVAVAX INC / NVAX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NOVAVAX INC?

ChartMill assigns a fundamental rating of 4 / 10 to NVAX.


What is the valuation status for NVAX stock?

ChartMill assigns a valuation rating of 3 / 10 to NOVAVAX INC (NVAX). This can be considered as Overvalued.


How profitable is NOVAVAX INC (NVAX) stock?

NOVAVAX INC (NVAX) has a profitability rating of 5 / 10.


What are the PE and PB ratios of NOVAVAX INC (NVAX) stock?

The Price/Earnings (PE) ratio for NOVAVAX INC (NVAX) is 3.88 and the Price/Book (PB) ratio is -11.91.


Can you provide the financial health for NVAX stock?

The financial health rating of NOVAVAX INC (NVAX) is 3 / 10.